CN111050755A - 一种胃滞留的胆汁酸螯合剂剂型的效果 - Google Patents

一种胃滞留的胆汁酸螯合剂剂型的效果 Download PDF

Info

Publication number
CN111050755A
CN111050755A CN201880048426.0A CN201880048426A CN111050755A CN 111050755 A CN111050755 A CN 111050755A CN 201880048426 A CN201880048426 A CN 201880048426A CN 111050755 A CN111050755 A CN 111050755A
Authority
CN
China
Prior art keywords
patient
dosage form
weeks
study
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880048426.0A
Other languages
English (en)
Chinese (zh)
Inventor
马克·G·科里
阿玛德·哈沙什
伯纳德·约瑟夫·拉文斯
迈克尔·霍尔
席尔瓦·卡拉西克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ironwood Pharmaceuticals Inc
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Priority to CN202210282827.0A priority Critical patent/CN114767646A/zh
Publication of CN111050755A publication Critical patent/CN111050755A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Otolaryngology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880048426.0A 2017-07-19 2018-07-19 一种胃滞留的胆汁酸螯合剂剂型的效果 Pending CN111050755A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210282827.0A CN114767646A (zh) 2017-07-19 2018-07-19 一种胃滞留的胆汁酸螯合剂剂型的效果

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762534591P 2017-07-19 2017-07-19
US62/534,591 2017-07-19
US201862681633P 2018-06-06 2018-06-06
US62/681,633 2018-06-06
PCT/US2018/042904 WO2019018656A1 (en) 2017-07-19 2018-07-19 EFFICACY OF A DOSAGE FORM OF BILIARY ACID SEQUESTERING AGENT WITH GASTRIC RETENTION

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210282827.0A Division CN114767646A (zh) 2017-07-19 2018-07-19 一种胃滞留的胆汁酸螯合剂剂型的效果

Publications (1)

Publication Number Publication Date
CN111050755A true CN111050755A (zh) 2020-04-21

Family

ID=65015306

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880048426.0A Pending CN111050755A (zh) 2017-07-19 2018-07-19 一种胃滞留的胆汁酸螯合剂剂型的效果
CN202210282827.0A Pending CN114767646A (zh) 2017-07-19 2018-07-19 一种胃滞留的胆汁酸螯合剂剂型的效果

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210282827.0A Pending CN114767646A (zh) 2017-07-19 2018-07-19 一种胃滞留的胆汁酸螯合剂剂型的效果

Country Status (9)

Country Link
US (2) US20200138854A1 (https=)
EP (1) EP3654953A4 (https=)
JP (1) JP2020527580A (https=)
CN (2) CN111050755A (https=)
AU (1) AU2018302255A1 (https=)
BR (1) BR112020001071A2 (https=)
CA (1) CA3070082A1 (https=)
MA (1) MA49653A (https=)
WO (2) WO2019018639A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115201357A (zh) * 2022-06-17 2022-10-18 陕西盘龙医药研究院 一种小儿咽扁颗粒中猪去氧胆酸的限量检测方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110579541B (zh) * 2019-08-29 2022-04-08 北京悦康科创医药科技股份有限公司 一种兰索拉唑有关物质的检测方法
CN110596295A (zh) * 2019-10-21 2019-12-20 上海百趣生物医学科技有限公司 一种检测胆汁酸的方法
CN111005074A (zh) * 2019-12-19 2020-04-14 江西海普洛斯医学检验实验室有限公司 一种基于illumina测序平台的DNA文库构建试剂盒、文库构建方法和应用
CN111060643B (zh) * 2020-01-16 2021-04-02 博莱克科技（武汉）有限公司 一种含有同分异构体胆汁酸代谢组分分离方法
CN111812264B (zh) * 2020-07-09 2021-06-15 苏州旭辉检测有限公司 一种去氧胆酸类化合物的生物样品分析方法
CN114146184A (zh) * 2021-12-03 2022-03-08 成都施桂行医药科技有限责任公司 阳离子聚合物在制备药物中的应用
CN114235995A (zh) * 2021-12-03 2022-03-25 天津国科医工科技发展有限公司 检测血清中15种胆汁酸的方法
WO2025043046A1 (en) * 2023-08-22 2025-02-27 GlycosBio, INC. Latex-compatible oil-based compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140105851A1 (en) * 2008-06-26 2014-04-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing gastrointestinal disorders and gerd-related respiratory disorders
US20160015644A1 (en) * 2013-01-15 2016-01-21 Ironwood Pharmaceuticals, Inc. Gastro-retentive sustained-release oral dosage form of a bile acid sequestrant

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120009130A1 (en) * 2010-05-06 2012-01-12 Nanoaxis Viral Therapy and Prophylaxis Using Nanotechnology Delivery Techniques
WO2011157655A1 (en) * 2010-06-15 2011-12-22 Biocrates Life Sciences Ag Use of bile acids for prediction of an onset of sepsis
WO2012027331A1 (en) * 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
MX346224B (es) * 2011-02-04 2017-03-10 Biocopea Ltd Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.
CN102729224B (zh) * 2012-07-05 2016-04-27 南京德朔实业有限公司 具有辅助弹出电池包功能的电动工具
US20180015118A1 (en) * 2015-02-03 2018-01-18 Ironwood Pharmaceuticals, Inc. Methods of treating upper gastrointestinal disorders in ppi refractory gerd
WO2017070114A2 (en) * 2015-10-18 2017-04-27 Wei Jia Diabetes-related biomarkers and treatment of diabetes-related conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140105851A1 (en) * 2008-06-26 2014-04-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing gastrointestinal disorders and gerd-related respiratory disorders
US20160015644A1 (en) * 2013-01-15 2016-01-21 Ironwood Pharmaceuticals, Inc. Gastro-retentive sustained-release oral dosage form of a bile acid sequestrant

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115201357A (zh) * 2022-06-17 2022-10-18 陕西盘龙医药研究院 一种小儿咽扁颗粒中猪去氧胆酸的限量检测方法

Also Published As

Publication number Publication date
WO2019018639A1 (en) 2019-01-24
AU2018302255A1 (en) 2020-02-06
US20200138854A1 (en) 2020-05-07
CA3070082A1 (en) 2019-01-24
EP3654953A4 (en) 2021-05-19
MA49653A (fr) 2021-05-19
BR112020001071A2 (pt) 2020-07-14
CN114767646A (zh) 2022-07-22
US20230190662A1 (en) 2023-06-22
JP2020527580A (ja) 2020-09-10
WO2019018656A1 (en) 2019-01-24
EP3654953A1 (en) 2020-05-27

Similar Documents

Publication Publication Date Title
CN111050755A (zh) 一种胃滞留的胆汁酸螯合剂剂型的效果
Omar et al. Drug treatment for faecal incontinence in adults
Zambrowicz et al. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes
TW202128183A (zh) 用於治療多種病症之方法及組成物
CN112533611A (zh) 19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
Zheng et al. Effects of estrogen with and without progestin and obesity on symptomatic gastroesophageal reflux
KR20230106644A (ko) S1p1 수용체와 관련된 상태를 치료하는 방법
US20230398127A1 (en) Use of combined oral contraceptives containing nomegestrol acetate and estradiol
Clearfield Clinical intestinal gas syndromes
US12616703B2 (en) Methods of contraception using nomegestrol acetate and estradiol
Singh et al. ORP-101 in Irritable
RU2851101C2 (ru) 19-nor с3,3-замещенный с21-n-пиразолилстероид и способы его применения
JP2026511098A (ja) 糖尿病性胃不全麻痺を治療するための方法
Gordon Obstetrics, Gynecology & Infertility: Handbook for Clinicians
WO2008043740A1 (en) Use of lansoprazole for the treatment of frequent heartburn
Lin Condom use lowers genital herpes risk
KOROUKIAN Health Maintenance
Miller Effect of School-Based Fitness Programs on Overweight Children
Slawson Watchful Waiting Acceptable Option for Inguinal Hernia
Ebell Many Patients with Barrett's Esophagus Have No Reflux
Henry Above-and Below-Elbow Casts for Children Are Similar
Wellbery Effect of Three Health Diets on Cardiovascular Markers
Betti et al. Speak Out.
Slawson Toremifene Is Effective Therapy for Mastalgia
Slawson Aspirin Lowers Cardiovascular Risk in Men and Women

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200421